COMMUNIQUÉS West-GlobeNewswire

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
07/11/2025
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be [...]
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...
07/11/2025
ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la [...]
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
07/11/2025
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies Dr. Adrian Bot, a renowned biopharmaceutical founder and scientist, has joined [...]
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
07/11/2025
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant [...]
Vaxart to Host Upcoming Conference Calls
07/11/2025
Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- [...]
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
07/11/2025
The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS (Vafidemstat) Received feedback from the FDA [...]
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
07/11/2025
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash [...]
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
07/11/2025
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years and older compared [...]
Major shareholder announcement
07/11/2025
Please read the full announcement in PDF Attachments 2025_47_Major_Shareholders_Announcement Novozymes B 05 November 2025_Final
Fangzhou, Novo Nordisk Launch Initiative for AI-Powered Diabetes and Weight Management Solutions at CIIE
07/11/2025
SHANGHAI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, was invited to the “Boundless Care, New Beginnings” [...]
Research Update
07/11/2025
Scancell Holdings plc Scancell holds oral presentation of positive Phase 2 data on Immunobody ® iSCIB1+ in late-stage melanoma at SITC 2025 Data from SCOPE trial show a potential new benchmark i n efficacy, durability, [...]
Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Re-source Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting
07/11/2025
PRESS RELEASE Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant [...]
Built for Peace of Mind: How HomeInherit Serves Seniors
07/11/2025
HomeInherit develops a senior-first home equity model built on clarity, safety, and community trust. HomeInherit Logo SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- HomeInherit, a senior-focused financial services [...]
React19 Launches “This Is Our Shot” Campaign as U.S. Vaccine Injury Victims Continue to Go Unheard and Uncompensated
07/11/2025
Patient-led nonprofit has already distributed $1.4 million in aid, challenging the federal government’s injury program SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- As the federal government’s Countermeasures Injury [...]
Kelyniam Global Renews Licensing Agreement with Finceramica, Unlocking Access to Valuable Pipeline Products
07/11/2025
CANTON, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and cranio-maxillofacial implants, today announced the renewal of its licensing agreement with [...]
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
07/11/2025
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the [...]
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
07/11/2025
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart demonstrated a [...]
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
07/11/2025
LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
VitalHub Reports Third Quarter 2025 Results
06/11/2025
Annual Recurring Revenue (ARR)⁽¹⁾ up 75% YoY to $93.7 million Total Revenue up 94% YoY to $32.0 million Adjusted EBITDA⁽¹⁾ up 58% YoY to $7.2 million TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) ( [...]

Pages